← Leaderboards
Budd A Tucker
University Of Iowa
$8,644,636
Attributed
$17,415,517
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,415,517 · 13
By mechanism
R01$13,455,060 · 8
DP2$2,262,500 · 1
R21$1,697,957 · 4
Top collaborators
- Robert Foster Mullins31 shared
- Edwin M Stone15 shared
- Todd E Scheetz6 shared
- David M Gamm4 shared
- Elaine Binkley2 shared
- John H Fingert2 shared
- Krzysztof Palczewski1 shared
- Kimerly Ann Powell1 shared
Most similar at University Of Iowa
Same institution · by research overlap
- John H Fingert$7,300,582
- Michael G Anderson$5,875,752
- Robert Foster Mullins$9,156,220
- Edwin M Stone$8,505,416
- Todd E Scheetz$3,840,332
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsBlindnessInduced Pluripotent Stem CellPhotoreceptorsProgramsAffectRetinaFunctional DisorderAge Related Macular DegenerationMolecularGenesEndothelial CellsMediatingStructure Of Retinal Pigment EpitheliumCessation Of LifeBlood VesselsMaculaCell DeathDrusenComplementChoroidInjuryComplement Membrane Attack ComplexIn Vitro
Grant awards (42)
Editing AMD Risk Alleles in Human Cells$620,149
R01 · FY2025 · EY
Non-destructive assessment of retinal differentiation capacity and developmental maturity$618,600
R01 · FY2025 · EY · contact PI
Choriocapillaris Protection and Replacement in AMD$405,654
R01 · FY2025 · EY
Molecular Studies of the Choriocapillaris in AMD$386,250
R01 · FY2025 · EY
A Next Generation Outer Retinal Microphysiological System$386,250
R01 · FY2025 · EY · contact PI
Sustained Treatment of wet AMD$366,523
R01 · FY2025 · EY · contact PI
Label-free microfluidic isolation of patient iPSC-derived photoreceptor cells$194,375
R21 · FY2025 · EY · contact PI
Stem cell approaches to normal tension glaucoma$194,375
R21 · FY2025 · EY
Choriocapillaris Protection and Replacement in AMD$405,654
R01 · FY2024 · EY
Molecular Studies of the Choriocapillaris in AMD$386,250
R01 · FY2024 · EY
A Next Generation Outer Retinal Microphysiological System$386,250
R01 · FY2024 · EY · contact PI
Sustained Treatment of wet AMD$366,523
R01 · FY2024 · EY · contact PI
Stem cell approaches to normal tension glaucoma$233,250
R21 · FY2024 · EY
Label-free microfluidic isolation of patient iPSC-derived photoreceptor cells$233,250
R21 · FY2024 · EY · contact PI
Choriocapillaris Protection and Replacement in AMD$405,654
R01 · FY2023 · EY
A Next Generation Outer Retinal Microphysiological System$386,250
R01 · FY2023 · EY · contact PI
Molecular Studies of the Choriocapillaris in AMD$386,250
R01 · FY2023 · EY
Molecular Studies of the Choriocapillaris in AMD$386,250
R01 · FY2022 · EY
A Next Generation Outer Retinal Microphysiological System$386,250
R01 · FY2022 · EY · contact PI
Choriocapillaris protection and replacement in AMD$374,663
R01 · FY2022 · EY
CRISPR-Cas9 based treatment of dominant retinal degeneration$374,300
R01 · FY2022 · EY
Molecular Pathophysiology of Von Hippel Lindau (VHL) disease$187,331
R21 · FY2022 · EY · contact PI
CRISPR-Cas9 based treatment of dominant retinal degeneration$378,902
R01 · FY2021 · EY
Choriocapillaris protection and replacement in AMD$374,662
R01 · FY2021 · EY
Molecular Pathophysiology of Von Hippel Lindau (VHL) disease$231,750
R21 · FY2021 · EY · contact PI
CRISPR-Cas9 based treatment of dominant retinal degeneration$394,890
R01 · FY2020 · EY
Choriocapillaris protection and replacement in AMD$386,250
R01 · FY2020 · EY
Molecular Basis of Complement Defense in Choroidal Endothelial Cells$193,125
R21 · FY2020 · EY · contact PI
Choriocapillaris protection and replacement in AMD$385,416
R01 · FY2019 · EY
Molecular Basis of Complement Defense in Choroidal Endothelial Cells$230,501
R21 · FY2019 · EY · contact PI
Disease Mechanisms in Best Disease$491,519
R01 · FY2018 · EY
CRISPR/Cas9-mediated correction of mutations that cause inherited retinal degenerations$343,125
R01 · FY2018 · EY
Disease Mechanisms in Best Disease$491,519
R01 · FY2017 · EY
Choriocapillaris Protection and Replacement in AMD$377,500
R01 · FY2017 · EY
CRISPR/Cas9-mediated correction of mutations that cause inherited retinal degenerations$343,125
R01 · FY2017 · EY
Disease Mechanisms in Best Disease$491,519
R01 · FY2016 · EY
Choriocapillaris Protection and Replacement in AMD$377,500
R01 · FY2016 · EY
CRISPR/Cas9-mediated correction of mutations that cause inherited retinal degenerations$342,282
R01 · FY2016 · EY
Disease Mechanisms in Best Disease$501,681
R01 · FY2015 · EY
Choriocapillaris Protection and Replacement in AMD$369,950
R01 · FY2015 · EY
Choriocapillaris Protection and Replacement in AMD$377,500
R01 · FY2014 · EY
Development of a cell replacement therapy to treat retinal degenerative blindness$2,262,500
DP2 · FY2010 · OD · contact PI